Stockreport

Pyxis Oncology: Data Arriving Later Than Expected, But May Be Worth The Wait [Seeking Alpha]

Pyxis Oncology, Inc.  (PYXS) 
PDF Initial data from the phase 1 trials of PYX-106 and PYX-201 are now expected in H2'24 and fall 2024 respectively. PYXS raised $50M in gross proceeds with a private pl [Read more]